Direct measure of the levels of HER2 total protein and its activated form, the HER2 homodimer - trastuzumab's target

• 15-20% of patients identified by conventional technologies as HER2 Negative expected to be reclassified by HERmark.
• Highly sensitive, detects HER2 levels from 2,500 to over 1 million receptors per cell (7 - 10x more sensitive than IHC).
• HERmark quantification of HER2 levels provides additional confidence for trastuzumab response.
• Current HERmark clinical data suggests correlation to therapy response in metastatic breast cancer.